Whenever life throws a challenge my way, I tell myself, “I was born for this.” I reminded myself of this while I went through a year of cancer treatment. It may seem like a strange thing to say to yourself, saying you’re born to face adversity, but that’s the kind of mindset that got me through a challenging time.
At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of triple combination venetoclax and obinutuzumab plus zanubrutinib.
ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL. This is a powerful combination with impressively durable responses in both TN and R/R patients.
We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.
We discussed an ongoing clinical trial currently recruiting patients to see if early intervention with venetoclax plus obinutuzumab can produce better outcomes for high-risk patients compared with traditional delayed therapy.
At the American Society of Hematology (ASH) 2021, Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center, interviewed Dr. Nitin Jain, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. They discussed early results from an ongoing study of a triple combination therapy with venetoclax, obinutuzumab, and atezolizumab, a PD-L1 checkpoint inhibitor.
Chairman of the Board and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the final results of a phase 1/2 clinical trial of entospletinib combined with obinutuzumab in patients with relapsed/refractory CLL.
Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.
Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.
